NurExone Taps Israeli Healthcare Titan to Steer Commercialization

TORONTO and HAIFA, Israel – January 30, 2026 – In a move signaling a decisive shift toward commercial readiness, biotech firm NurExone Biologic Inc. has appointed Eyal Gabbai, a towering figure in Israel's healthcare and financial sectors, to its board of directors. The appointment is seen by analysts as a strategic masterstroke designed to pair the company's promising regenerative science with the high-level expertise required to navigate global capital markets and complex healthcare systems.

Mr. Gabbai, who currently chairs Israel's third-largest health fund, replaces Dr. Gadi Riesenfeld, who will transition to the company’s Scientific Advisory Board, ensuring scientific continuity. The change underscores a pivotal moment for NurExone as it prepares to advance its exosome-based therapies, particularly its lead candidate ExoPTEN for spinal cord injury, from preclinical success toward critical first-in-human trials.

A Pivot from Science to Market Strategy

For a preclinical biotechnology company, the appointment of a board member with Gabbai's profile is a significant statement. It reflects a maturing strategy that looks beyond the laboratory to the formidable challenges of market access, regulatory approval, and large-scale funding. NurExone is betting that Gabbai's unique blend of experience will be the catalyst it needs to transform scientific potential into tangible medical solutions.

“This appointment reflects our focus on engaging with partners who understand both patient needs and the economics of healthcare,” said Yoram Drucker, Chairman of NurExone, in a statement. “Eyal brings deep experience across healthcare systems, technology adoption, market implementation, as well as a strong understanding of public company and regulated environments.”

This sentiment is echoed in Gabbai's own rationale for joining the company. “I chose to join NurExone because of the strength of its technology and science and the disciplined way the team is approaching development in an area of medicine where current solutions are not good enough,” Gabbai stated. He highlighted the company's “dual outlook,” which balances the long-term development of proprietary drug candidates with nearer-term revenue opportunities from exosome supply and collaborations.

This strategic hire suggests NurExone is proactively building the commercial infrastructure and financial credibility needed for its next phase of growth. Bringing a leader who understands the intricacies of multi-billion-dollar healthcare budgets and public-market dynamics is a clear signal to investors that the company is planning for commercial success, not just scientific discovery.

The “National Privatizer” Enters the Biotech Arena

Eyal Gabbai’s curriculum vitae reads like a blueprint for navigating the intersection of government, finance, and large-scale enterprise. His reputation as a formidable manager and negotiator was forged during his tenure as Director General of Israel’s Government Companies Authority from 2002 to 2007. There, he earned the moniker “The National Privatizer” for orchestrating privatization and capital market transactions exceeding US$5 billion, including the strategic sales of national assets like airline El Al and telecom giant Bezeq.

His influence grew further when he served as Director-General of Israel’s Prime Minister’s Office, where he was a central figure in coordinating national economic policy. Currently, he sits at the helm of Meuhedet Health Fund, an organization with approximately 1.4 million members and an annual turnover of over US$3 billion. In this role, he has overseen major strategic moves, including the acquisition of private hospital networks and the development of new medical infrastructure, demonstrating a keen understanding of healthcare delivery on a massive scale.

This background is exceptionally relevant to NurExone. A company developing novel therapies for conditions like spinal cord and optic nerve injury must eventually convince large healthcare providers and insurers of its product's clinical and economic value. Gabbai's experience managing the budget and strategic direction of a major health fund provides NurExone with an insider’s perspective on how to position a new therapy for adoption and reimbursement.

Navigating the Future of Regenerative Medicine

NurExone operates at the cutting edge of regenerative medicine with its exosome-based platform. Exosomes are microscopic vesicles that act as natural messengers between cells, capable of delivering therapeutic payloads across biological barriers like the blood-brain barrier. The company's lead product, ExoPTEN, has shown strong preclinical data in reducing inflammation and promoting regeneration in models of acute spinal cord and optic nerve injury—both multi-billion-dollar markets with significant unmet needs.

The field of exosome therapy is one of immense promise, attracting investment from pharmaceutical giants, but it is also fraught with regulatory and manufacturing challenges. As advanced therapies, these treatments face a high bar for approval from bodies like the U.S. FDA and the European Medicines Agency. Securing an Orphan Drug Designation, which NurExone is pursuing, is a critical step in this journey, but it is only one of many.

This is where Gabbai’s experience in regulated environments becomes invaluable. His ability to engage with government counterparts, navigate complex policy, and structure large-scale financial transactions will be instrumental as NurExone seeks to fund its expensive clinical trials, optimize manufacturing processes, and build a global supply chain. His involvement provides a layer of strategic and financial gravitas that can help de-risk the company's ambitious development plans in the eyes of institutional investors and potential pharmaceutical partners.

The Israeli Biotech Nexus and Global Ambitions

The appointment also highlights NurExone's strategic position within the vibrant Israeli biotech ecosystem. With operations in both Haifa, Israel, and Toronto, Canada, and a U.S. subsidiary, Exo-Top Inc., the company has a distinctly international footprint. Gabbai’s deep connections within Israel’s political, financial, and healthcare establishments provide a powerful anchor for the company's global strategy.

His network can unlock strategic alliances, streamline regulatory engagement within Israel, and attract capital from a region known for its robust tech and life sciences investment culture. Meanwhile, the transition of Dr. Gadi Riesenfeld to the Scientific Advisory Board represents a shrewd move to retain deep institutional knowledge and scientific oversight. This ensures that as the board's focus expands to include commercial and financial strategy, the core science driving the company's value remains guided by expert hands.

By bringing Eyal Gabbai into its leadership circle, NurExone is not merely adding a new name to its board roster. It is making a clear, calculated move to equip itself with the leadership necessary to transition from a promising preclinical company into a commercial-stage biopharmaceutical contender on the global stage.